Akorn and Hi-Tech recall more than 900 gallons of dental rinse


U.S. OTC and generics maker Akorn ($AKRX) and its Hi-Tech Pharmacal unit have had a number of recalls lately involving its liquid products, including more than 7,200 bottles of dental mouth rinse which the FDA says failed impurities testing.

According to the FDA Enforcement Report, Akorn has three separate recalls of chlorhexidine gluconate oral rinse, amounting to 128 lots, that the agency said was out of specification for an unknown impurity. That amounts to about 909 gallons of the rinse. The company, which has headquarters in both the U.S. and India, began the voluntary recall of the products in late March, but the FDA just this week classified them as class II.

On top of that, the drugmaker is voluntarily recalling 57,920 bottles of sulfacetamide sodium ophthalmic solution that failed antimicrobial effectiveness testing.


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

Lake Forest, IL-based Akorn bought Hi-Tech in 2013 for $640 million and then grabbed VersaPharm the next year for $440 million in what CEO Raj Rai said was an effort to double its revenues. He has accomplished that and more, tripling revenues to $985 million last year from $317.7 million in 2013, after having to restate some financials tied to the two acquired companies.   

Along the way, Akorn has had some significant recalls when measured in quantities. Last year it recalled more than 355,000 bottles of its generic of Bactrim made for children after it was found to be out of specification for the dissolution of sulfamethoxazole, one of two active ingredients in the product. A couple of months later, it recalled hundreds of thousands of bottles of the generic anxiety drug hydroxyzine hydrochloride because it failed impurities specifications.

- find the recalls here 

Related Articles: 
Akorn's Hi-Tech source of another recall 
Akorn antibiotic recall stems from its buyout of Hi-Tech 
Akorn estimates it overstated '14 financials by $35M

Suggested Articles

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

As flights from China contract and prices double, the logistics of getting products out of China is a major challenge. 

A group of drugmakers and others say some federal policies to fight COVID-19 are it making more expensive and harder to get some drugs.